I would call it a Ponzi scheme. I think that's what you're going to see, a rare disease Ponzi scheme amongst the pharmaceuticals.
A drug company visited me about this. It bought a company that had one product and paid $800 million for it. They said to me that they would now have to charge a certain amount to make their money back. Who told them to go and spend $800 million on this product?
That's in the same breath with Mylan. That's what they've done. They sold the rights or whatever. Whoever it is who bought them, Recordati or whoever it is, can now justify saying that it is going to cost more money, that it is going to be extra.
I hear what you're saying, and I can imagine all my colleagues here are so frustrated that it's right there; I don't understand how it can't get done. I'm sure we're all very frustrated with that.
I'd like to ask Ms. Moore a question in regard to the clinical trials.
Any member of Parliament who's been doing this long enough, whether it's in our social circles or just out and around, we've all met people who have had ALS. It's terminal, and it's pretty tough to see that take place. When it's in a situation like that, what do we have to do to get it from six weeks to virtually immediate?